Susan Young Rojahn

A View from Susan Young Rojahn

Pfizer "Disappointed" with First Results for Alzheimer's Drug Candidate

Amyloid-recognizing drug has no effect in patients with a high-risk genetic background.

  • July 24, 2012

On Monday, Pfizer announced the first of four expected sets of results for its Alzheimer’s drug bapineuzumab. As Steven Romano, head of the company’s Medicines Development Group said in a release, Pfizer is “disappointed”: the drug had no effect on the cognition or day-to-day functioning of patients with the largest known genetic risk for the late-stage onset form of the disease (ApoE4 carriers).

Bapineuzumab is an antibody—a protein that selectively grabs onto a specific protein—that recognizes beta-amyloid, the protein that forms tell-tale plaques in Alzheimer’s patient’s brains (see “Brain Scan for Alzheimer’s”). Because they riddle the brains of patients with the disease, amyloid plaques are one of the major suspects in the enigmatic disease. However, whether these plaques are an instigator of Alzheimer’s or a byproduct of the disease is still a major question for the field.

The company will continue with its trials in patients who do not carry the ApoE4 genetic variant. Results are expected later this summer.

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Biomedicine

New technologies and biological insights are providing unprecedented ways of improving our health.

Want more award-winning journalism? Subscribe to Insider Plus.

  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

You've read of free articles this month.